Core Viewpoint - LeMaitre Vascular, Inc. is actively engaging with investors through presentations at two upcoming conferences in December 2024, highlighting its commitment to investor relations and market presence [1][2]. Company Overview - LeMaitre Vascular, Inc. specializes in devices, implants, and services for the treatment of peripheral vascular disease, which affects over 200 million people globally [3]. - The company develops, manufactures, and markets both disposable and implantable vascular devices tailored for vascular surgeons [3]. Upcoming Events - David Roberts, President of LeMaitre, will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 3:30 PM EST in New York City [1]. - Additionally, he is scheduled to present at the Stifel "MedTech Madness" West Coast Bus Tour on December 12, 2024, at 11:45 AM PST in Menlo Park, CA [2].

Topic 1: Financial Performance - [Key Point 1] Revenue increased by 15% year-over-year, driven by strong sales in the North American market. [1] - [Key Point 2] Net profit margin improved to 12%, up from 10% in the previous quarter. [2] - [Key Point 3] Operating expenses rose by 8%, primarily due to increased marketing and R&D investments. [3] Topic 2: Market Expansion - [Key Point 1] The company successfully entered the European market, with initial sales exceeding expectations. [1] - [Key Point 2] A new distribution center was opened in Asia to support regional growth. [4] - [Key Point 3] Strategic partnerships were formed with local retailers to enhance market penetration. [2] Topic 3: Product Development - [Key Point 1] Launched three new products in the last quarter, all of which received positive customer feedback. [3] - [Key Point 2] R&D spending increased by 20% to accelerate innovation and product differentiation. [4] - [Key Point 3] A new product line is scheduled for release next quarter, targeting the premium segment. [1] Topic 4: Operational Efficiency - [Key Point 1] Implemented new supply chain management software, reducing delivery times by 15%. [2] - [Key Point 2] Streamlined manufacturing processes, resulting in a 10% reduction in production costs. [3] - [Key Point 3] Enhanced inventory management systems to minimize stockouts and overstock situations. [4] Topic 5: Strategic Initiatives - [Key Point 1] Announced a new sustainability initiative aimed at reducing carbon emissions by 25% over the next five years. [1] - [Key Point 2] The company is exploring potential acquisitions to diversify its product portfolio. [2] - [Key Point 3] A new corporate governance framework was introduced to improve transparency and accountability. [3]

This updated analysis of LeMaitre Vascular (NASDAQ: LMAT ) takes a fresh look at the company from the perspective of a long-term, dividend growth investor. Since my last article in July, LeMaitre has continued to expand its footprint withinJoseph Jones, professor at The University of Southern Mississippi, has over fifteen years of experience studying the market. He focuses on portfolio construction from a dividend growth investor's perspective. The insights expressed in his research are solely his own; they ...

BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November. UBS Global Healthcare Conference Wednesday, November 13, 2024 Terranea Resort, Rancho Palos Verdes, CA David Roberts, President, will present at 7:15 AM PT Stifel's 2024 Healthcare Conference Tuesday, November 19, 2024 Lotte NY Palace Hotel, New York City David Roberts, President, will present at 1:50 PM ET Wolfe ...

Financial Data and Key Metrics - Q3 2024 sales growth was 16%, driven by 10% pricing and 6% unit growth [9] - Gross margin improved to 67.8%, up 280 basis points year-over-year, with Q4 guidance at 68% and full-year gross margin expected at 68.3% [16][17] - Operating income increased 43% year-over-year to $13.1 million, with an operating margin of 24% [17] - Cash and securities increased by $10.8 million to $124 million at the end of Q3 [18] - EPS grew 49% in Q3, with Q4 EPS guidance at $0.14 per share, up 30% [7][20] Business Line Performance - Grafts, patches, and carotid shunts grew 24%, 13%, and 18% respectively in Q3 [9] - Allograft product units grew 26%, and XenoSure product line units grew 10% [37] - RestoreFlow Allograft yields improved, contributing to gross margin expansion [16] Market Performance - APAC was the strongest region, with 24% growth, led by Thailand and Korea [9] - EMEA sales grew 22%, while the Americas grew 12% [9] - China sales increased 62% in Q3, driven by efforts in the region [11] - France saw 21% sales growth due to the new Paris office [10] Strategy and Industry Competition - The company is expanding its direct sales model with GoDirect projects in Portugal and Czechia, expected to begin in 2025 [12] - Regulatory progress includes 15 of 22 MDR CE marks received, with the remaining expected in 2025 [13] - Pricing floors have been implemented globally, contributing to a 9% average annual price increase from 2021 to 2024 [19] - The company is focusing on niche markets with differentiated products, enabling consistent price increases [29] Management Commentary on Operating Environment and Outlook - Management highlighted strong execution in pricing and operational efficiency, driving sales and margin growth [16] - The company expects continued healthy sales and profit growth for 2024 [14] - Regulatory approvals and international market expansion, particularly for allograft, remain key priorities [13] Other Important Information - The company is transitioning its CFO, with J.J. Pellegrino stepping down in March 2025 after 19 years [14] - A new CFO search is ongoing, with Russell Reynolds assisting in the process [14] - The company is consolidating its Shanghai sales office and warehouse into a larger facility [11] Q&A Session Summary Question: Geographic breakdown of price increases vs. unit growth [21] - Management did not provide a detailed geographic breakdown but acknowledged the need to prepare for such questions in future meetings [22] Question: Inventory levels and direct distribution ramp-up [23] - The company maintains ample inventory to fulfill its no-backorder promise and has capacity to triple factory output if needed [23] Question: Operating margin expansion drivers for 2025 [24] - Operating expense growth has slowed, and gross margin improvements are expected to continue, driven by direct labor efficiencies [25][26] Question: Sustainability of price increases [28] - The niche product strategy and pricing floors are expected to sustain price increases, with average annual hikes of 9% since 2021 [29][30] Question: Sales rep expansion and confidence in targets [31] - The company is confident in reaching its year-end target of 155-160 sales reps, with 149 currently onboard and more hires planned [32][33] Question: R&D spending trends [35] - R&D spending was lower in Q3 due to reduced regulatory costs, with potential benefits expected going forward [35] Question: Distribution strategy and brick-and-mortar expansion [38] - The company is pursuing distributor buyouts in Czechia and Portugal while expanding direct operations in China, France, and Switzerland [39][40] Question: Pricing strategy sustainability [41] - Pricing floors have proven effective, and the company expects continued pricing momentum [42] Question: Product-specific price increases [43] - Price increases are concentrated in high-market-share products like valvulotomes, shunts, and biologic grafts [43] Question: Top-line growth drivers [45] - Allograft sales grew 47%, and European market exits by competitors have created opportunities [46][47] Question: Sales rep expansion in Europe [50] - The company plans to add more reps in Europe, with nine open territories and additional needs in Czechia and Portugal [50] Question: XenoSure cardiac patch approval in China [52] - The final submission for XenoSure approval in China has been made, with a decision expected in six months [52] Question: CFO transition and qualifications [53] - The company is seeking a CFO with public company and med-tech experience, with a focus on technical expertise [55] Question: Gross margin sustainability [57] - Gross margins are expected to remain strong, supported by pricing and manufacturing efficiencies, though RestoreFlow growth may exert some pressure [57][58] Question: M&A activity and valuation trends [59] - The company is exploring larger acquisitions, with a focus on strategic fit and financial discipline [60][61] Question: Leverage capacity for large deals [62] - The company could finance deals up to $300 million, combining bank debt and excess cash [65] Question: Price floor rollout status [68] - Price floors have been implemented in major markets, with potential for further expansion [68] Question: Allograft approval timelines in Ireland and Germany [69] - Delays in Germany and Ireland due to regulatory and logistical challenges may push approvals into 2025 or 2026 [69][70] Question: Impact of pending MDR CE marks [73] - The allograft approval is the most impactful, with other approvals having less immediate significance due to existing MDD CE marks [73] Question: M&A discipline and deal timing [74] - The company remains disciplined in its M&A approach, focusing on the right deal at the right price [74][75] Question: Targeting cardiac surgeons and sales force strategy [77] - Cardiac sales account for 14% of total sales, with potential for dedicated cardiac reps in the future [77][78] Question: Cross-selling opportunities with growing sales force [79] - The U.S. offers low-hanging fruit for cross-selling, with plans to split high-performing territories [79]

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.36%. A quarter ago, it was expected that this medical device maker would post earnings of $0.47 per share when it actually produced earnings of $0.52, delivering a surprise of 10.64%.Over the last four quarter ...

BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results Sales $54.8mm, +16% (+16% organic) vs. Q3 2023Gross margin 67.8%, +280 bpsOp. income $13.1mm, +43%Op. margin 24%Earnings per diluted share $0.49, +46%Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sale ...

Exhibit 99.1 LeMaitre Q3 2024 Financial Results BURLINGTON, MA, October 31, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results ● Sales $54.8mm, +16% (+16% organic) vs. Q3 2023 ● Gross margin 67.8%, +280 bps ● Op. income $13.1mm, +43% ● Op. margin 24% ● Earnings per diluted share $0.49, +46% ● Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches ...

BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access th ...

BURLINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference Wednesday, September 4, 2024 New York Marriott Marquis, New York, NY David Roberts, President, will present at 5:35 PM EST Barrington Research Fall Investment Conference (Virtual) Thursday, September 12, 2024 George W. LeMaitre, Chairman & CEO, is scheduled ...